We Are One Seven LLC raised its position in Novartis AG (NYSE:NVS) by 5.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 40,619 shares of the company’s stock after buying an additional 2,154 shares during the quarter. Novartis comprises about 1.0% of We Are One Seven LLC’s holdings, making the stock its 13th largest position. We Are One Seven LLC’s holdings in Novartis were worth $3,846,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Palisade Asset Management LLC boosted its position in shares of Novartis by 3.2% during the 4th quarter. Palisade Asset Management LLC now owns 22,880 shares of the company’s stock worth $2,167,000 after purchasing an additional 713 shares in the last quarter. Wedbush Securities Inc. boosted its position in shares of Novartis by 1.1% during the 4th quarter. Wedbush Securities Inc. now owns 18,657 shares of the company’s stock worth $1,767,000 after purchasing an additional 205 shares in the last quarter. Reilly Financial Advisors LLC boosted its position in shares of Novartis by 4.7% during the 4th quarter. Reilly Financial Advisors LLC now owns 137,157 shares of the company’s stock worth $12,987,000 after purchasing an additional 6,118 shares in the last quarter. Hemenway Trust Co LLC boosted its position in shares of Novartis by 0.6% during the 4th quarter. Hemenway Trust Co LLC now owns 206,294 shares of the company’s stock worth $19,534,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Cullinan Associates Inc. boosted its position in shares of Novartis by 31.7% during the 4th quarter. Cullinan Associates Inc. now owns 6,076 shares of the company’s stock worth $575,000 after purchasing an additional 1,464 shares in the last quarter. 10.62% of the stock is currently owned by institutional investors.
Shares of NYSE NVS traded up $0.50 during trading on Thursday, hitting $95.10. 1,441,139 shares of the company were exchanged, compared to its average volume of 1,275,271. The company has a market cap of $216.80 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 1.95 and a beta of 0.59. Novartis AG has a 1 year low of $74.70 and a 1 year high of $95.66. The firm’s fifty day moving average price is $93.70 and its 200 day moving average price is $90.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 0.95 and a quick ratio of 0.73.
Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 22nd. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.31 by $0.10. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The company had revenue of $12.17 billion for the quarter, compared to analyst estimates of $11.67 billion. During the same period in the previous year, the firm earned $1.32 EPS. The business’s revenue was up 10.5% on a year-over-year basis. On average, research analysts forecast that Novartis AG will post 5.23 earnings per share for the current year.
Several equities research analysts have commented on NVS shares. ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. Cowen restated a “buy” rating and set a $100.00 target price on shares of Novartis in a research report on Friday, October 25th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $93.34.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Article: Diversification Important in Investing
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.